Ranbaxy Sees "Progress" On Discussions With U.S. FDA, DOJ; Keeps Lipitor Launch Hopes Alive
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - After staying non-committal for several months, Daiichi-Sankyo controlled Ranbaxy Laboratories Ltd. now says it has engaged in wide-ranging negotiations with U.S. FDA and the Department of Justice on multiple issues related to the alleged violation of good manufacturing practices at two of its India-based sites in Paonta Sahib and Dewas
You may also be interested in...
U.S. FDA Issues Warning For Contamination At Cadila's India Site
MUMBAI - U.S. FDA has issued a warning letter to India's Cadila Healthcare Ltd. citing significant violations of current good manufacturing practices at its Sarkhej plant, near the Western city of Ahmedabad. The facility was inspected between Jan.17 and Feb. 3
U.S. FDA Issues Warning For Contamination At Cadila's India Site
MUMBAI - U.S. FDA has issued a warning letter to India's Cadila Healthcare Ltd. citing significant violations of current good manufacturing practices at its Sarkhej plant, near the Western city of Ahmedabad. The facility was inspected between Jan.17 and Feb. 3